Meridian Health Ventures

Meridian Health Ventures, formerly known as KHP Ventures, is a London-based venture firm with a distinctive position as the world’s first NHS-anchored transatlantic fund. The firm operates at the intersection of UK clinical innovation and U.S. commercial scaling, supporting healthtech founders whose technologies have been validated within NHS clinical environments and who are ready to enter the U.S. market.

The thesis covers digital health, AI/ML in healthcare, and health IT, with a clear preference for companies whose products can be deployed and validated within large NHS clinical environments before scaling internationally. AI sits centrally in the firm’s view of where healthcare is moving, particularly in clinical workflow, decision support, and operational tooling. The fund’s NHS anchoring gives it unusual access to clinical pilot opportunities, which is one of the most valuable assets a UK healthtech founder can secure.

Meridian invests at Seed and Series A with check sizes of $1M to $5M. Geographic focus is the United Kingdom and North America, with the firm’s transatlantic mandate making it an unusually relevant partner for UK companies looking to enter the U.S. healthcare market or U.S. companies seeking validation in a major single-payer system. Founders should expect a partner that is comfortable leading or co-leading rounds, taking board seats, and engaging substantively on commercial strategy across both markets.

The team brings clinical, operational, and investing backgrounds, with deep relationships into NHS leadership and a working understanding of U.S. healthcare commercialization. Decisions move through a focused partnership process, and diligence typically includes substantive engagement with NHS clinical leaders who can assess the fit of a product within real care pathways. This produces tougher feedback than founders might receive from purely financial investors, but the upshot is that approved investments arrive with strong clinical credibility.

Meridian’s working approach is hands-on and oriented toward bridging the UK-US healthcare divide. Portfolio founders gain access to structured NHS pilot opportunities, introductions to U.S. health system buyers, and ongoing strategic support around regulatory pathway, reimbursement design, and commercial expansion. For UK founders, the firm offers an unusual combination of domestic clinical access and international scaling support, which is a gap that few European VCs fill effectively. Reporting expectations are professional and aligned with the cadence of clinical and commercial milestones, with quarterly board engagement and active between-meeting collaboration on strategic questions. The firm will not be the right fit for founders building products without clinical relevance to the NHS or for those uninterested in eventual U.S. market entry, but for healthtech founders building AI and software products that benefit from rigorous clinical validation and transatlantic scale, Meridian Health Ventures represents a focused and well-positioned partner with a clear mandate, a credible network, and a thesis that aligns well with where healthcare innovation funding has consolidated.